In this work, we report how the CK1 inhibitor, named IGS2.7 (Salado et al., 2014), and the TTBK1 inhibitor, called VNG1.47 (Nozal et al., 2022), are able not only to recover the TDP-43 homeostasis in lymphoblastoid cell lines of severe AD patients, but also to stop the cell-to-cell transmission of the TDP-43 pathology in this kind of cells. Here, TTBK1 is linked to Alzheimer disease.